Wednesday, December 28, 2022 11:49:57 AM
I know right? LOL. Even crazy is that the the company with a new tech galectin cure (Kill rate of 100% in days of Covid19) that is just starting a phase I/II in India, that while it elliminates the virus 100% in days, it will not deal with 1/3 of the people that already suffer from long haul covid, which $RVTTF Buccilamine would be perfect for, and IMO, Bucillamine could/should be used with the galectin once they are both approved, and that stock is up 50% today headed back to a $ land level, and fools are selling $RVVTF at a dime that is 2-3 years ahead of it in late phase III FDA EUA process....
Christmas gifts here in $RVVTF land....
Great to have you on board here $RVTF
Christmas gifts here in $RVVTF land....
Great to have you on board here $RVTF
Bullish
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
